Pure Global
NCT05200741

To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2

A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 as Booster Vaccine for COVID-19 in Healthy Adults Who Have Received 2 Doses of BNT162b2
The University of Hong Kong·Phase 2·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Covid19
Drug/Device/Intervention
DelNS1-2019-nCoV-RBD-OPT1
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
The University of Hong Kong
Location
Hong Kong, China
Timeline & enrollment
Phase
Phase 2
Start date
Feb 08, 2022
End date
Feb 01, 2024
Enrollment
150 participants
Primary outcome

Reactogenicity,Adverse Events,Neutralizing Antibodies in Serum against Live SARS-CoV-2 Measured by Neutralization Assay,Binding Antibodies in Serum against SARS-CoV-2 RBD Measured by CMIA

Summary

To evaluate the safety and immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 as booster vaccine for
 COVID-19 in healthy adults who have received 2 doses of BNT162b2

ICD-10 classifications
COVID-19, virus identifiedCOVID-19, virus not identifiedCoronavirus infection, unspecified siteRift Valley feverPlague
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05200741
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05200741 through Pure Global AI's free database. This Phase 2 trial is sponsored by The University of Hong Kong and is currently Recruiting. The study focuses on Covid19. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.